傳恆大(03333.HK)擬蝕讓元朗和生圍項目 惟乏人問津
早前傳出中國恆大(03333.HK)計劃以80億元「蝕讓價」出售元朗和生圍項目,不過《南華早報》引述業界消息指出,由於土地成本高昂,而且缺乏詳細的大型項目藍圖,很少有買家願意出手收購該項目。戴德梁行香港資本市場部執行董事高偉雄認為,恆大或因償債壓力的增加而愈來愈迫切想要出售資產,潛在買家可能會等待恆大作出更大的折扣時才有所行動。
高偉雄續稱,雖然已問過許多開發商意向,惟他們幾乎都認為和生圍項目開發周期較長,銷售時間亦長,要賣如此大規模的項目亦較為困難。
據悉,恆大原計劃於和生圍項目建造268幢洋房,整個項目的總住宅樓面約89.3萬平方呎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.